Cardiovascular disease (CVD) is the number one cause of mortality globally 1
TS23, an alpha-2 antiplasmin antibody, offers a novel paradigm shift in thrombolysis
If absorption trade-offs are acceptable given your goals and your provider agrees, oral BPC-157 may be reviewed as part of your plan
doi:10.3390/nu5125031
This study was carried out in accordance with the recommendations of the respective Institutional Review Boards (IRBs), described below with written informed consent from parents of subjects and assent where appropriate
Phase 1: Consultation and Assessment (Week 0) Comprehensive history and physical examination Review of prior imaging, surgical reports, and treatment history Discussion of goalsreturn to sport, pain reduction, GI symptom resolution, etc